αααααβααΎαDNA β’ NYSE
add
Ginkgo Bioworks Holdings Inc
7.85$
αααααααααα(4.14%)-0.32
7.53$
ααΆααα·αα 17 ααααΆ, 4:24:01 PM ααααβααα -4 · USD · NYSE · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·αααΆαααΈααααΆααααΆααααααΆααα
α’αΆαααα·α
αα·αααΈαα»α
8.09$
α
αααααααααααα
7.28$ - 8.10$
α
ααααααα½αααααΆαα
α»αααααα
5.00$ - 45.20$
ααΎαβαα»αβααΈααααΆα
432.01Β ααΆα USD
ααα ααα½αααΌαααααα
1.46Β ααΆα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NYSE
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(USD) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 43.85Β ααΆα | 26.16% |
α
αααΆαααααα·ααααα·ααΆα | 128.36Β ααΆα | -29.52% |
α
αααΌααα»ααα | -107.53Β ααΆα | 49.20% |
ααααΆααα
αααααα»ααα | -245.25 | 59.74% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -1.21 | 58.78% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -78.48Β ααΆα | 44.39% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 0.30% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(USD) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 561.57Β ααΆα | -40.52% |
ααααααααα»α | 1.38Β αααΈααΆα | -17.29% |
ααΆαααα½ααα»αααααΌαααα»α | 661.39Β ααΆα | 16.40% |
ααΌαβααααα»α | 716.06Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 54.37Β ααΆα | β |
ααααααααααΉαααααα
| 0.61 | β |
ααα
ααααααΎαααααα | -16.47% | β |
ααα
ααααααΎααΎααα»α | -19.39% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(USD) | ααααΌ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | -107.53Β ααΆα | 49.20% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -42.44Β ααΆα | 26.62% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -13.08Β ααΆα | 71.97% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -203.00Β ααΆαα | 67.88% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -55.80Β ααΆα | 46.88% |
ααα αΌαααΆα
αααααΆααααααα | -64.47Β ααΆα | -146.17% |
α’αααΈ
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
2008
ααΆαα·ααΆαααβαααααΆα
αααααβαααααΆα
αα»ααααα·α
834